Cargando…
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) has one of the highest mortality rates among solid cancers. Late diagnosis and a lack of efficacious treatment options contribute to the dismal prognosis of HCC. Immune checkpoint inhibitor (ICI)-based immunotherapy has presented a new milestone in the treatment of can...
Autores principales: | Ji, Jun Ho, Ha, Sang Yun, Lee, Danbi, Sankar, Kamya, Koltsova, Ekaterina K., Abou-Alfa, Ghassan K., Yang, Ju Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144688/ https://www.ncbi.nlm.nih.gov/pubmed/37108802 http://dx.doi.org/10.3390/ijms24087640 |
Ejemplares similares
-
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
por: Dika, Imane El, et al.
Publicado: (2017) -
Hepatocellular carcinoma, novel therapies on the horizon
por: El Dika, Imane, et al.
Publicado: (2020) -
Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022) -
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021) -
ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)